Business, energy, technology, markets and global industry news from Business News Today

non-small cell lung cancer

PharmaDeviceNews non-small cell lung cancer
Verastem Oncology advances its VS-7375 development programme as the TARGET-D 202 Phase 2 trial begins evaluating the investigational KRAS G12D inhibitor in previously treated advanced non-small cell lung cancer. Representative image.
Pharma & Biotech

Verastem has entered the KRAS G12D lung cancer race, but can VS-7375 close the evidence gap?

Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.

Read More
Representative image: Advanced blood-based molecular residual disease testing illustrates Natera’s Signatera expansion in Europe following IVDR certification across multiple cancers.
Medical Devices & Diagnostics

Natera just cleared a major European hurdle for Signatera, but can hospitals turn certification into adoption?

Natera’s Signatera gains European IVDR certification across multiple cancers, opening a new phase for personalized MRD testing and clinical adoption.

Read More
Representative image: Clinician reviewing lung CT scans, reflecting MAIA Biotechnology’s ateganosine data in third-line non-small cell lung cancer and the evolving search for new NSCLC treatment strategies.
Pharma & Biotech

MAIA Biotechnology reports stronger ateganosine data in third-line non-small cell lung cancer

MAIA Biotechnology has reported positive initial efficacy data from Part C of the Phase 2 THIO-101 expansion trial evaluating ateganosine followed by cemiplimab in third-line advanced non-small cell lung cancer. The clinical-stage oncology drug developer said the regimen produced a 90.5 percent interim disease control rate among efficacy-evaluable patients, placing its telomere-targeting strategy back in

Read More
Abbisko Therapeutics and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated non-small cell lung cancer, putting safety, pneumonitis risk and treatment durability under close scrutiny. Representative image.
Pharma & Biotech

AstraZeneca adds Abbisko’s lumipodlin to expanding Tagrisso combination strategy

Discover why Abbisko and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated lung cancer.

Read More
Representative image: Samsung Bioepis’ SB27 Keytruda biosimilar trial results highlight a potentially important step toward lower-cost pembrolizumab competition in the global oncology market.
Pharma & Biotech

Samsung Bioepis SB27 meets Phase 3 endpoint as Keytruda biosimilar competition accelerates

Read how Samsung Bioepis SB27’s positive Phase 1 and Phase 3 data could reshape the Keytruda biosimilar race and oncology access.

Read More
Representative image: An oncology specialist reviews lung scans and clinical trial data as Pfizer’s sigvotatug vedotin Phase 3 survival miss shifts attention to second-line patients, biomarker strategy and first-line combinations.
Pharma & Biotech

Sigvotatug vedotin Phase 3 miss tests Pfizer’s case for integrin beta-6 targeted ADCs

Discover why Pfizer’s sigvotatug vedotin Phase 3 miss shifts attention to second-line patients, biomarkers and first-line combinations.

Read More
Representative image: Clinicians review lung cancer genomic testing data and blood-based diagnostic results, reflecting Guardant Health’s Guardant360 CDx FDA approval as a companion diagnostic for HERNEXEOS in HER2-mutant advanced non-small cell lung cancer.
Medical Devices & Diagnostics

How Guardant360 CDx approval supports Boehringer Ingelheim’s HERNEXEOS launch strategy

Find out how Guardant360 CDx approval could expand liquid biopsy use in HER2-mutant advanced lung cancer treatment selection.

Read More
Representative image: GSK’s $10.6 billion Nuvalent deal puts precision lung cancer therapies in focus as Big Pharma races to secure late-stage oncology assets.
Pharma & Biotech

Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions

GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.

Read More
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Pharma & Biotech

Why MAIA Biotechnology’s ateganosine program is entering a decisive lung cancer development phase

Find out how MAIA Biotechnology’s ateganosine trials could shape the next phase of lung cancer drug development today.

Read More